The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.
 
Lijuan Jiang
No Relationships to Disclose
 
Xia Zheng
No Relationships to Disclose
 
Wensu Wei
No Relationships to Disclose
 
Yulu Peng
No Relationships to Disclose
 
Deling Wang
No Relationships to Disclose
 
Zhiling Zhang
No Relationships to Disclose
 
Shengjie Guo
No Relationships to Disclose
 
Hui Han
No Relationships to Disclose
 
Xiuyu Cai
No Relationships to Disclose
 
Fangjian Zhou
No Relationships to Disclose
 
Pei Dong
No Relationships to Disclose